Global Regulatory Requirements


The US FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. CDISC and FDA have worked together closely since CDISC’s inception to ensure data standards allow regulatory reviewers to receive, process, review and archive submissions more effectively.

The FDA is a Platinum Member of CDISC Standards and CDISC Standards are required for regulatory submissions to FDA.


The Japan PMDA continues to improve the public health and safety of Japan by reviewing applications for marketing approval of pharmaceuticals and medical devices, conducting safety measures, and providing relief to people who have suffered from adverse drug reactions.

The PMDA is a Platinum Member of CDISC and CDISC Standards are required for regulatory submissions to the PMDA.


The China NMPA is responsible for supervising the safety of drugs (including traditional Chinese medicines and ethno-medicines), medical devices and cosmetics; regulating the registration of drugs, medical devices and cosmetics; and undertaking standards management for drugs, medical devices and cosmetics.

CDISC standards are now the preferred standards for electronic data submission in China as stipulated in the eCTD Guidance (September 2019).

Read CDISC’s official response (Chinese and English) to the NMPA request for public comments on the draft eCTD guidance.

Helpful Links

From FDA:


From PMDA: